US5234212A
(en)
*
|
1992-07-06 |
1993-08-10 |
Dutra Jr Joseph G |
Document receiving tray assembly and method of using such
|
DK0678122T3
(da)
*
|
1993-01-12 |
2000-03-06 |
Biogen Inc |
Rekombinante anti-VLA4 antistofmolekyler
|
EP0682529B2
(en)
*
|
1993-02-09 |
2005-12-28 |
Biogen Idec MA, Inc. |
Antibody for the treatment of insulin dependent diabetes
|
US5677291A
(en)
*
|
1993-12-10 |
1997-10-14 |
Hoechst Marion Roussel, Inc. |
Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
EP1759709B1
(en)
*
|
1994-01-25 |
2013-02-27 |
Elan Pharmaceuticals Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
FR2724393A1
(fr)
*
|
1994-09-12 |
1996-03-15 |
Inst Nat Sante Rech Med |
Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
|
US7750137B2
(en)
|
1995-09-01 |
2010-07-06 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressins
|
US7803904B2
(en)
|
1995-09-01 |
2010-09-28 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressing and uses thereof
|
US6551593B1
(en)
|
1995-02-10 |
2003-04-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
|
US5608095A
(en)
*
|
1996-04-30 |
1997-03-04 |
Hoechst Marion Roussel, Inc. |
Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
|
US5795876A
(en)
*
|
1996-04-30 |
1998-08-18 |
Hoechst Marion Rousssel, Inc. |
Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
US6114572A
(en)
*
|
1996-11-20 |
2000-09-05 |
Hoechst Marion Roussel, Inc. |
Substituted phenols and thiophenols useful as antioxidant agents
|
US6121463A
(en)
*
|
1997-06-24 |
2000-09-19 |
Hoechst Marion Roussel, Inc. |
Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
|
US6133467A
(en)
*
|
1997-06-25 |
2000-10-17 |
Hoechst Marion Roussel, Inc. |
2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
|
DE19741235A1
(de)
|
1997-09-18 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
DE19741873A1
(de)
*
|
1997-09-23 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
DE19751251A1
(de)
|
1997-11-19 |
1999-05-20 |
Hoechst Marion Roussel De Gmbh |
Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
|
EP2180007B2
(en)
|
1998-04-20 |
2017-08-30 |
Roche Glycart AG |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
DE19821483A1
(de)
|
1998-05-14 |
1999-11-18 |
Hoechst Marion Roussel De Gmbh |
Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
ES2319831T3
(es)
|
1998-09-14 |
2009-05-12 |
Board Of Regents, The University Of Texas System |
Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.
|
US7618630B2
(en)
|
1998-09-14 |
2009-11-17 |
Board Of Regents, The University Of Texas System |
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
|
EP2264166B1
(en)
*
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
CN1191860C
(zh)
|
1999-04-22 |
2005-03-09 |
比奥根公司 |
利用整联蛋白α4亚单位的拮抗剂治疗纤维变性的方法
|
DE19922462A1
(de)
|
1999-05-17 |
2000-11-23 |
Aventis Pharma Gmbh |
Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
SI2314315T1
(sl)
|
1999-06-01 |
2015-04-30 |
Biogen Idec Ma Inc. |
Blokirno monoklonsko protitelo proti humani alfa1 i-domeni vla-1 in njegova uporaba za zdravljenje vnetnih obolenj
|
JP4975922B2
(ja)
*
|
1999-09-14 |
2012-07-11 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
1つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
|
US20060115473A1
(en)
*
|
2000-12-14 |
2006-06-01 |
Biogen Idec Ma Inc., A Massachusetts Corporation |
Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
|
JP2003517023A
(ja)
|
1999-12-16 |
2003-05-20 |
バイオジェン インコーポレイテッド |
中枢神経系の虚血性損傷または出血性損傷を、抗α4インテグリンアンタゴニストを用いて処置する方法
|
JP3459609B2
(ja)
*
|
2000-03-17 |
2003-10-20 |
三洋電機株式会社 |
ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
AU2016204535C1
(en)
*
|
2000-04-12 |
2017-02-23 |
Laboratoire Français Du Fractionnement Et Des Biotechnologies |
Anti-D monoclonal antibodies
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
DE10111877A1
(de)
|
2001-03-10 |
2002-09-12 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
MXPA03009390A
(es)
|
2001-04-13 |
2004-01-29 |
Biogen Inc |
Anticuerpos para integrina vla-1.
|
DE10137595A1
(de)
|
2001-08-01 |
2003-02-13 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
|
NZ581474A
(en)
|
2001-08-03 |
2011-04-29 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
DE60332093D1
(de)
|
2002-02-20 |
2010-05-27 |
Ajinomoto Kk |
Neues phenylalaninderivat
|
ATE512163T1
(de)
|
2002-02-25 |
2011-06-15 |
Elan Pharm Inc |
Verabreichung von mitteln zur behandlung von entzündungen
|
US20050069541A1
(en)
|
2003-01-24 |
2005-03-31 |
Karlik Stephen J. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
WO2004092220A1
(en)
*
|
2003-04-14 |
2004-10-28 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations
|
US7485291B2
(en)
*
|
2003-06-03 |
2009-02-03 |
Cell Genesys, Inc. |
Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
US7498024B2
(en)
*
|
2003-06-03 |
2009-03-03 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
|
US7691810B2
(en)
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
US7496938B2
(en)
*
|
2003-11-24 |
2009-02-24 |
Sabic Innovative Plastics Ip B.V. |
Media drive with a luminescence detector and methods of detecting an authentic article
|
JP4743659B2
(ja)
|
2003-12-22 |
2011-08-10 |
味の素株式会社 |
新規フェニルアラニン誘導体
|
KR20070009581A
(ko)
*
|
2004-02-06 |
2007-01-18 |
엘란 파마슈티칼스, 인크. |
종양 및 전이성 질환 치료 방법 및 조성물
|
US7419666B1
(en)
|
2004-02-23 |
2008-09-02 |
Massachusetts Eye And Ear Infirmary |
Treatment of ocular disorders
|
US20050276803A1
(en)
*
|
2004-04-16 |
2005-12-15 |
Genentech, Inc. |
Method for augmenting B cell depletion
|
US7714119B2
(en)
*
|
2004-07-13 |
2010-05-11 |
Biosante Pharmaceuticals, Inc. |
AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
GB0420771D0
(en)
*
|
2004-09-17 |
2004-10-20 |
Randox Lab Ltd |
Antibody
|
WO2006055871A2
(en)
*
|
2004-11-19 |
2006-05-26 |
Biogen Idec Ma Inc. |
Treatment for multiple sclerosis
|
EP1833509A4
(en)
*
|
2004-12-03 |
2008-12-03 |
Biogen Idec Inc |
DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
|
EP2332408B1
(en)
|
2005-02-17 |
2013-11-13 |
Biogen Idec MA Inc. |
Treating neurological disorders
|
CN101166542A
(zh)
|
2005-03-02 |
2008-04-23 |
比奥根艾迪克Ma公司 |
用于治疗th2介导的疾病的kim-1抗体
|
US7678371B2
(en)
|
2005-03-04 |
2010-03-16 |
Biogen Idec Ma Inc. |
Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
|
KR20140068234A
(ko)
|
2005-03-31 |
2014-06-05 |
더 제너럴 하스피탈 코포레이션 |
Hgf/hgfr 활성의 모니터링 및 조정
|
PL3264094T3
(pl)
|
2005-04-04 |
2021-04-19 |
Biogen Ma Inc. |
Sposoby oceniania odpowiedzi immunologicznej na środek leczniczy
|
US7632509B2
(en)
*
|
2005-07-19 |
2009-12-15 |
Biosante Pharmaceuticals, Inc. |
Methods to express recombinant proteins from lentiviral vectors
|
JP2009508470A
(ja)
*
|
2005-07-21 |
2009-03-05 |
アボット・ラボラトリーズ |
Sorf構築物並びにポリタンパク質、プロタンパク質及びタンパク質分解による方法を含む複数の遺伝子発現
|
TWI428143B
(zh)
|
2006-01-18 |
2014-03-01 |
Gen Hospital Corp |
增加淋巴功能之方法
|
JP2009528359A
(ja)
*
|
2006-02-28 |
2009-08-06 |
エラン ファーマシューティカルズ,インコーポレイテッド |
ナタリズマブを用いて炎症性疾患および自己免疫性疾患を治療する方法
|
WO2007100763A2
(en)
*
|
2006-02-28 |
2007-09-07 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
KR20080104343A
(ko)
*
|
2006-03-03 |
2008-12-02 |
엘란 파마슈티칼스, 인크. |
나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
|
WO2007123737A2
(en)
|
2006-03-30 |
2007-11-01 |
University Of California |
Methods and compositions for localized secretion of anti-ctla-4 antibodies
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
US20070292922A1
(en)
*
|
2006-03-31 |
2007-12-20 |
Cell Genesys, Inc. |
Regulated expression of recombinant proteins from adeno-associated viral vectors
|
EP2839843B1
(en)
*
|
2006-05-25 |
2018-06-20 |
Biogen MA Inc. |
VLA-1 antagonist for use in treating stroke
|
US8288110B2
(en)
*
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
US20100150915A1
(en)
|
2007-02-20 |
2010-06-17 |
Stewart Edward J |
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
|
EP2170390B1
(en)
*
|
2007-06-14 |
2018-11-07 |
Biogen MA Inc. |
Natalizumab antibody formulations
|
ES2824261T3
(es)
|
2007-09-14 |
2021-05-11 |
Biogen Ma Inc |
Composiciones y procedimientos para el tratamiento de la leucoencefalopatía multifocal progresiva (LMP)
|
EP2085407A1
(en)
|
2008-02-04 |
2009-08-05 |
Sahltech I Göteborg AB |
Treatment of idiopathic thrombocytopenic purpura
|
JP5639039B2
(ja)
|
2008-04-11 |
2014-12-10 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
US9096681B2
(en)
|
2008-06-02 |
2015-08-04 |
Dana-Farber Cancer Institute, Inc. |
XBP1, CD138, and CS1 peptides
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
JP5677972B2
(ja)
|
2008-11-18 |
2015-02-25 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
SG175166A1
(en)
*
|
2009-04-17 |
2011-11-28 |
Biogen Idec Inc |
Compositions and methods to treat acute myelogenous leukemia
|
EP2467159A1
(en)
|
2009-08-20 |
2012-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
|
EP3349010A1
(en)
|
2009-10-11 |
2018-07-18 |
Biogen MA Inc. |
Anti-vla-4 related assays
|
US8623368B2
(en)
|
2009-10-23 |
2014-01-07 |
Hanwha Chemical Corporation |
Human recombinant monoclonal antibody that specifically binds to VCAM-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
|
KR20120091251A
(ko)
*
|
2009-10-30 |
2012-08-17 |
아보트 러보러터리즈 |
Sorf 작제물 및 다중 유전자 발현
|
HUE060312T2
(hu)
|
2010-01-11 |
2023-02-28 |
Biogen Ma Inc |
A JC vírus antitestek vizsgálata
|
US11287423B2
(en)
|
2010-01-11 |
2022-03-29 |
Biogen Ma Inc. |
Assay for JC virus antibodies
|
ME03813B
(me)
|
2010-04-16 |
2021-04-20 |
Biogen Ma Inc |
Anti-vla-4 antitela
|
CN103221422B
(zh)
|
2010-07-29 |
2017-03-29 |
十一生物治疗股份有限公司 |
嵌合il‑1受体i型激动剂和拮抗剂
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP2632492B1
(en)
|
2010-10-25 |
2017-10-04 |
Biogen MA Inc. |
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
JP6211931B2
(ja)
|
2011-03-09 |
2017-10-11 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
モノクローナル抗体を作製するための方法および試薬
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
PE20141672A1
(es)
|
2011-05-02 |
2014-11-26 |
Millennium Pharm Inc |
FORMULACION PARA ANTICUERPO ANTI-alfa4�7
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
SG10201602654SA
(en)
|
2011-10-03 |
2016-05-30 |
Moderna Therapeutics Inc |
Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
|
EP2769223A1
(en)
|
2011-10-17 |
2014-08-27 |
Westfälische Wilhelms-Universität Münster |
Assessment of pml risk and methods based thereon
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
WO2013123114A2
(en)
|
2012-02-16 |
2013-08-22 |
Santarus, Inc. |
Antibody formulations
|
HUE044838T2
(hu)
|
2012-03-20 |
2019-11-28 |
Biogen Ma Inc |
JCV neutralizáló antitestek
|
AU2013243950A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9717453B2
(en)
|
2012-04-20 |
2017-08-01 |
Biogen Idec Ma Inc. |
Cognitive composite parameters and uses thereof for evaluating multiple sclerosis
|
EA030716B1
(ru)
|
2012-05-14 |
2018-09-28 |
Байоджен Ма Инк. |
Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
|
EP2883177A1
(en)
|
2012-08-13 |
2015-06-17 |
Biogen Idec MA Inc. |
Disease progression parameters and uses thereof for evaluating multiple sclerosis
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
BR112015007780A2
(pt)
|
2012-10-09 |
2017-11-28 |
Biogen Idec Inc |
molécula de anticorpo anti-lingo-1, seu uso para tratamento de distúrbios desmielinantes, kit e composição embalada
|
US9950047B2
(en)
|
2012-11-05 |
2018-04-24 |
Dana-Farber Cancer Institute, Inc. |
XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
ES2884813T3
(es)
|
2013-03-13 |
2021-12-13 |
Buzzard Pharmaceuticals AB |
Formulaciones de citoquina quimérica para administración ocular
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3004334A4
(en)
|
2013-05-28 |
2016-12-21 |
Biogen Ma Inc |
METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML
|
WO2015038777A1
(en)
|
2013-09-11 |
2015-03-19 |
Arsia Therapeutics, Inc. |
Liquid protein formulations containing water soluble organic dyes
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
WO2015063604A2
(en)
|
2013-11-01 |
2015-05-07 |
Imberti Luisa |
BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
|
US20170216434A1
(en)
*
|
2014-08-05 |
2017-08-03 |
Wayne State University |
Compositions and methods for treatment of sickle cell disease
|
MX2017004306A
(es)
|
2014-10-01 |
2017-12-20 |
Eagle Biologics Inc |
Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
|
AU2016205197B2
(en)
|
2015-01-08 |
2021-10-21 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
CA2988306A1
(en)
|
2015-06-05 |
2016-12-08 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
SG11201811704SA
(en)
|
2016-07-13 |
2019-01-30 |
Biogen Ma Inc |
Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
|
WO2018045162A1
(en)
|
2016-09-01 |
2018-03-08 |
Biogen Ma Inc. |
Biomarkers predictive of primary progressive multiple sclerosis and uses thereof
|
WO2018106641A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles for the treatment of demyelinating diseases
|
WO2018106646A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Aminotriazoles for the treatment of demyelinating diseases
|
WO2018106643A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic azoles for the treatment of demyelinating diseases
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
JP7457661B2
(ja)
|
2018-06-04 |
2024-03-28 |
バイオジェン・エムエイ・インコーポレイテッド |
低減したエフェクター機能を有する抗vla-4抗体
|
UY38605A
(es)
|
2019-03-11 |
2020-09-30 |
Biogen Ma Inc |
Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1
|
US11339061B2
(en)
|
2020-02-05 |
2022-05-24 |
Garron M. Hobson |
Solar water pasteurizer
|
EP4153317A1
(en)
|
2020-05-19 |
2023-03-29 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
|
EP4340942A1
(en)
|
2021-05-18 |
2024-03-27 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
|